Previous 10 | Next 10 |
Micro-cap Histogen ([[HSTO]] +173.4%) after announcing preliminary week 18 results from its Phase 1b/2a trial evaluating HST-001 in androgenic alopecia (male pattern baldness).At the week 18 primary efficacy endpoint, patients treated with HST-001 demonstrated separation from placebo for...
HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated w ith No Serious Adverse Events Week 26 Fina...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today anno...
Histogen (HSTO) to sell ~2.52M common shares at $1.78375/share, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of ~$4.5M.Concurrently, the company will issue unregistered five and one-half years warrants to purchase 1,892,088 common shares at $1.70...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today anno...
Histogen (HSTO): Q3 GAAP EPS of -$0.27.Revenue of $0.49M (+58.1% Y/Y)Cash and cash equivalents of $6.6M.Press Release For further details see: Histogen reports Q3 results
Topline Data for HST-001 Phase 1b/2a Trial for Androgenic Alopecia in Men on Track for 4Q20 Received $2M Grant Award from the Department of Defense for Clinical Advancement of HST-003 for Cartilage Regeneration in the Knee Appointed Moya Daniels as Executive Vice Pre...
SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today an...
Histogen (HSTO) ticks 2% higher in premarket on light volume after announcing an agreement with Amerimmune to jointly develop emricasan a caspase inhibitor, for the treatment of COVID-19.Additionally, the FDA has signed-off Phase 1 study of emricasan in mild-COVID-19 patie...
Histogen Receive s IND A pproval from FDA to Initiate a Phase 1 Study of Emricasan in M ild-COVID - 19 Patients to Assess Safety and Tolerability Amerimmune to Lead Development Efforts of Emricasan in a ...
News, Short Squeeze, Breakout and More Instantly...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...